Myocardial infarction (heart attack) occurs when coronary blood flow is severely reduced or blocked, causing ischemic injury and necrosis of heart muscle. It is a major cause of cardiovascular morbidity and mortality.
Cadrenal Therapeutics received FDA guidance for a pivotal Phase 3 trial of CAD-1005 in HIT after an End-of-Phase 2 meeting. Phase 2 data showed a >25% absolute reduction in thrombotic events. The company also plans a Phase 2a trial in cardiac surgery-associated AKI.
mRNA medicine and spatiotemporal drug delivery systems are expanding options for cardiovascular disease. The sources describe preclinical proof-of-concept, clinical trials and programmable cardiac repair platforms.
A study in the American Journal of Medicine found that U.S. adults with the highest ultraprocessed food intake had higher cardiovascular disease risk. Mean ultraprocessed food intake was 26.1% of total energy.
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
A study of over 83,000 women found that initiating hormone therapy after age 65 significantly increases risks for cancer and cerebrovascular events, reinforcing current guidelines that discourage starting systemic hormone therapy after age 60.
CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.
The global 3D bioprinted human tissue market is projected to grow from $2.5 billion in 2025 to $3.9 billion by 2035 at a 4.6% CAGR, driven by regenerative medicine demand and advances in hybrid hydrogel materials for tissue engineering.
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07783880 |
Investigation to Assess the Effects of Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes |
NOT_YET_RECRUITING | NA |
| NCT07764588 |
Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction |
RECRUITING | |
| NCT07727135 |
Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation |
NOT_YET_RECRUITING | NA |
| NCT07706816 |
Evaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study |
NOT_YET_RECRUITING | NA |
| NCT07701109 |
Individualized Discharge Education in High-Risk Myocardial Infarction Patients |
NOT_YET_RECRUITING | NA |
| NCT07696390 |
The Effect of Virtual Reality Application Diagnosed With Myocardial Infarction |
RECRUITING | NA |
| NCT07693712 |
Senescence in Myocardial Infarction |
TERMINATED | |
| NCT07636642 |
Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study |
RECRUITING | NA |
| NCT07624240 |
Educational Dietary Intervention in Early Cardiac Rehabilitation After Myocardial Infarction |
COMPLETED | NA |
| NCT07620119 |
Machine Learning for Diagnosis of Occlusive MI in LBBB Patients |
RECRUITING |
